

Federica Papaccio

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2539505/publications.pdf>

Version: 2024-02-01

26
papers

1,895
citations

393982

19
h-index

610482

24
g-index

26
all docs

26
docs citations

26
times ranked

4038
citing authors

#	ARTICLE	IF	CITATIONS
1	Detection of postoperative plasma circulating tumour DNA and lack of CDX2 expression as markers of recurrence in patients with localised colon cancer. <i>ESMO Open</i> , 2020, 5, e000847.	2.0	21
2	Precision Medicine to Treat Advanced Gastroesophageal Adenocarcinoma: A Work in Progress. <i>Journal of Clinical Medicine</i> , 2020, 9, 3049.	1.0	12
3	Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer. <i>Cancers</i> , 2020, 12, 3611.	1.7	30
4	Circulating cancer stem cells: an interesting niche to explore. <i>Exploration of Targeted Anti-tumor Therapy</i> , 2020, 1, 253-258.	0.5	4
5	Glucose-6-phosphate dehydrogenase blockade potentiates tyrosine kinase inhibitor effect on breast cancer cells through autophagy perturbation. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 160.	3.5	59
6	Urtica dioica L. inhibits proliferation and enhances cisplatin cytotoxicity in NSCLC cells via Endoplasmic Reticulum-stress mediated apoptosis. <i>Scientific Reports</i> , 2019, 9, 4986.	1.6	15
7	In the literature: August 2018. <i>ESMO Open</i> , 2019, 4, e000563.	2.0	0
8	Ex vivo lung cancer spheroids resemble treatment response of a patient with NSCLC to chemotherapy and immunotherapy: case report and translational study. <i>ESMO Open</i> , 2019, 4, e000536.	2.0	26
9	The role of chemotherapy in localized and locally advanced rectal cancer: A systematic revision. <i>Cancer Treatment Reviews</i> , 2018, 63, 156-171.	3.4	34
10	HGF/MET and the Immune System: Relevance for Cancer Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3595.	1.8	78
11	Prognostic Nutritional Index as an independent prognostic factor in locoregionally advanced squamous cell head and neck cancer. <i>ESMO Open</i> , 2018, 3, e000425.	2.0	39
12	HDAC2 depletion promotes osteosarcoma stemness both in vitro and in vivo: a study on a putative new target for CSCs directed therapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 296.	3.5	49
13	A new inhibitor of glucose-6-phosphate dehydrogenase blocks pentose phosphate pathway and suppresses malignant proliferation and metastasis in vivo. <i>Cell Death and Disease</i> , 2018, 9, 572.	2.7	138
14	Concise Review: Cancer Cells, Cancer Stem Cells, and Mesenchymal Stem Cells: Influence in Cancer Development. <i>Stem Cells Translational Medicine</i> , 2017, 6, 2115-2125.	1.6	232
15	Results of the safety run-in part of the METAL (METformin in Advanced Lung cancer) study: a multicentre, open-label phase II study of metformin with erlotinib in second-line therapy of patients with stage IV non-small-cell lung cancer. <i>ESMO Open</i> , 2017, 2, e000132.	2.0	61
16	Pharmacological targeting of the ephrin receptor kinase signalling by GLPG1790 in vitro and in vivo reverts oncophenotype, induces myogenic differentiation and radiosensitizes embryonal rhabdomyosarcoma cells. <i>Journal of Hematology and Oncology</i> , 2017, 10, 161.	6.9	29
17	Implication of the Hedgehog pathway in hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2017, 23, 4330.	1.4	54
18	Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells. <i>Oncotarget</i> , 2016, 7, 4265-4278.	0.8	58

#	ARTICLE	IF	CITATIONS
19	Pulmonary Large-Cell Neuroendocrine Carcinoma: From Epidemiology to Therapy. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1133-1141.	0.5	212
20	SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 4686-4697.	3.2	103
21	A Multicenter, Open-Label Phase II Study of Metformin With Erlotinib in Second-Line Therapy of Stage IV Non-Small-Cell Lung Cancer Patients: Treatment Rationale and Protocol Dynamics of the METAL Trial. <i>Clinical Lung Cancer</i> , 2015, 16, 57-59.	1.1	16
22	Stemness markers of osteosarcoma. , 2015, , 205-211.		1
23	Increased fucosylation has a pivotal role in invasive and metastatic properties of head and neck cancer stem cells. <i>Oncotarget</i> , 2015, 6, 71-84.	0.8	66
24	Role of HGF-MET Signaling in Primary and Acquired Resistance to Targeted Therapies in Cancer. <i>Biomedicines</i> , 2014, 2, 345-358.	1.4	30
25	Cancer stem cells in solid tumors: an overview and new approaches for their isolation and characterization. <i>FASEB Journal</i> , 2013, 27, 13-24.	0.2	338
26	Human primary bone sarcomas contain CD133 ⁺ cancer stem cells displaying high tumorigenicity <i>in vivo</i> . <i>FASEB Journal</i> , 2011, 25, 2022-2030.	0.2	190